National Medical Research Radiological Center of the Ministry of Health of Russia (NMRRC) is the first scientific medical cluster in Russia for oncology, radiology and urology. Today, the Center has three branches: P.Hertsen Moscow Oncology Research Institute (MORI), A.Tsyb Medical Radiology Research Center (MRRC) and N.Lopatkin Research Institute of Urology and Interventional Radiology.
With the merger of the three leading Russian research institutes, the task for the NMRRC is to become one of the world leaders in nuclear medicine.
The status of the National Center has significantly expanded the patients’ ability to receive all aspects of modern high-tech medical care: from surgery using photodynamic therapy and chemotherapy intraoperatively to radiation therapy and radiosurgery. Every year, the Center launches new technologies and methods to treat patients.
In 2019, for the first time in Russia, liver radioembolization with the use of Russian microsources was performed in A.Tsyb MRRC - a branch of NMRRC. The use of this highly effective method allows to stop tumor growth in almost 90% of patients and increase life expectancy by 4-5 times compared to other standard methods of treatment. For NMRRC this method of treatment has become a strategic one under the Program for the development of modern methods of cancer treatment in Russia.
In November 2019, the world's first brachytherapy operation on advanced breast cancer using alpha particles was performed under international protocol on the A.Tsyb site. Russian specialists performed this operation with their colleagues from Israel, Germany and the USA. One of the advantages of this method is that it does not only destroy the tumor, but also stimulates immune system, which begins to fight metastases itself.
In 2019, the N.Lopatkin Research Institute of Urology and Interventional Radiology celebrated its 40th anniversary. Largely thanks to support of the Ministry of Health of the Russian Federation and to Minister Prof. V.Skvortsova personally, the Centre launched modern laboratories fitted with the latest-generation equipment for clinical diagnostic and molecular genetic studies, an MRI room and an Urodynamics Department, which has no analog in Europe, a new 50-bed unit, Children's department, ICUs and new cutting-edge operating rooms. Another very important milestone was the launch of the modernized Hemodialysis Center with 20 artificial kidney devices, with the capability to perform 2000 procedures per month.
The center has a high scientific potential. It gave birth to a galaxy of scientists who are engaged in fundamental research and development and its translation into practice, in creating new antitumor drugs for cancer treatment. Experimental studies and clinical trials of the new drugs are conducted in the Center. Thus, in 2019, for the purpose of developing additive technologies, NMRRC purchased a modern 3D bioprinter to print and culture three-dimensional cellular structures. Tests are currently underway.
On December 10th, P.Hertsen MORI together with the 3D Bioprinting Solution Laboratory (Invitro company), completed a set of preclinical trials on the skin regeneration in experimental rats using 3D bioprinting with a robotic arm (Cook company, Germany). It was done inside the operating room. Specialists of P.Hertsen MORI made the restoration gel out of a patient’s cells. Thus, the implant will not be rejected.
The center actively cooperates with the Russian Academy of Sciences (RAS) and other Russian and foreign research institutes, corporations, industrial associations. In 2019 alone, NMRRC signed 14 agreements on cooperation aimed at the development of scientific and clinical potential. Of a particular importance was conclusion of the Russian-Japanese Memorandum on construction of Russia's first ion therapy center in September 2019. The Center for the treatment of cancer with heavy carbon ions will be built in Obninsk.
In 2019, a new international project on telemedicine was launched with the leading medical centers of Tokyo and Osaka (Japan). It was agreed to set up a telepathology platform in the Center that would allow to get “second opinion” through telemedicine consultations, exchange scientific data and conduct joint researches.
In June 2019, NMRRC signed an agreement with Bulgarian Charitable Foundation on provision of the proton therapy treatment to Bulgarian patients.
Another significant milestone in 2019 was conclusion of the Russian-Kazakh agreements on telemedicine consultations, including for the provision of second opinion on the pathological material by the Center’s specialists.
In September 2019, during the Second International Forum on Oncology and Radiology, NMRRC signed agreements with members of the Association for Directors of Institutes of Oncology and Radiology of the CIS and Eurasia (ADIOR): the Center of Oncology and Radiology of the Republic of Uzbekistan and the State Oncology Institute of Serbia. Both agreements are on cooperation in education and exchange of experience in diagnostics and cancer treatment.
In 2019, on the initiative of NMRRC the First International Congress on Rare Tumors was held in Russia. The congress was a platform that brought together more than 800 Russian and foreign specialists in order to discuss modern scientific achievements, the latest medical experience and technologies in the field of diagnostics and treatment of orphan diseases, as well as to develop solutions and recommendations for specialists, including those involved in primary care, on effective diagnostics and treatment of this type of diseases.
In November 2019, an unprecedented event took place in Berlin - the Russian-German Forum "Nuclear medicine - the alchemy of modern oncology", which brought together the world's leading experts. This was the first time Russian scientists had initiated such event within the program of the Berlin Science Week and presented their own developments and technologies in the field of nuclear medicine.
In 2019, on NMRRC initiative and with the support of the Federation Council of the Federal Assembly of the Russian Federation, the Ministry of Health of Russia, and the Association of Oncologists of Russia, all-Russian educational project “Oncopatrol” was launched. The project is extraordinary by its geographic coverage. Its goal is to promote a healthy lifestyle and to increase oncological alertness among citizens of the Russian Federation. The essence of the project is that NMRRC oncologists go to different regions of Russia and together with specialists of the regional oncology dispensaries examine employees of the largest enterprises of the city in accordance with the program on early detection of oncological diseases for men and women. Employees of the enterprise have the opportunity to check their health before or after the work shift. So far, 7 subjects of the Russian Federation have participated in the project: Moscow, Yaroslavl, Moscow, Voronezh, Kursk, Samara regions and the Republic of Bashkortostan. 1878 people were examined, 16 cases with suspected cancer and 124 cases with pathologies of various localizations were identified.
NMRRC Press Service